clinical trial · NCT05655520
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Huntington's DiseaseSAGE-718
brief summary
The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)
started
Dec 14, 2022
primary completion
Jan 20, 2025
completion
Jan 20, 2025
last updated
Dec 17, 2025
official title
A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol